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ABSTRACT
Chronic graft-versus-host-disease (cGVHD) is a major barrier to successful allogeneic hematopoietic stem cell
transplantation (allo-HSCT), with highly variable clinical presentations. The pathophysiology of cGVHD re-
mains relatively poorly understood. The utilization ofmurinemodels to study cGVHDencompasses experimen-
tal challenges distinct from those that have been successfully used to study acute GVHD (aGVHD).
Nevertheless, despite these challenges, murine models of cGVHD have contributed to the understanding of
cGVHD, and highlight its mechanistic complexity. In this article, insights into the pathophysiology of cGVHD
obtained from murine studies are summarized in the context of their relevancy to clinical cGVHD. Despite ex-
perimental limitations, current and future models of murine cGVHD will continue to provide insights into the
understanding of clinical cGVHD and provide information for new therapeutic interventions.
 2008 American Society for Blood and Marrow Transplantation
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Chronic graft-versus-host disease (cGVHD) re-
mains a significant barrier to successful allogeneic he-
matopoietic stem cell transplantation (allo-HSCT).
The incidence of cGVHD following allo-HSCT
ranges from 25%-80%, and is associated with signifi-
cant morbidity and mortality [1], despite the fact that
cGVHD is also associated with a lower relapse rate
presumably because of graft-versus-tumor effects [2].
Clinical manifestations of cGVHD are highly variable
with respect to organ involvement and extent, and fur-
ther complicated by differentmethodologies of clinical
scoring to define disease severity [3].
These challenges in cGVHD have been addressed
in a series of efforts in the clinical community [3-8]. It
is now recognized that cGVHD is a distinct clinical
entity from acute GVHD (aGVHD) and not merely
a temporal extension of the latter [9]. Pathophysiolog-
ically, in aGVHD, necrotic changes to target organs
(skin, liver, and gastrointestinal tract) predominate
the pathologic phenotype. In contrast, fibrosis and
chronic inflammation of target organs, oftenincluding the same target organs in aGVHD, are the
pathologic hallmarks of cGVHD [1]. These differ-
ences in the phenotypic outcomes, which largely paral-
lel manifestations in humans, delineate murine models
of aGVHD and cGVHD (Table 1). Not surprisingly,
the immune mechanisms that are implicated in the
induction and propagation of cGVHD have been
shown to be distinct from those of aGVHD.
Chronic GVHD evolves as a consequence of dys-
regulated alloreactive reactions between donor-de-
rived immune cells and host cell populations. In
contrast to aGVHD, the immune mechanisms leading
to the development of cGVHD remain more incom-
pletely understood. There are a number of factors
that account for this. First, the clinical features of
cGVHD until recently, with the establishment of the
National Institutes of Health Consensus Project on
cGVHD [3], have not been defined in a systematic
and objective fashion so that assessments of cGVHD
have varied from institution to institution. Second,
the clinical features of cGVHD themselves are highly
variable and mimic, but not completely replicate, a va-
riety of autoimmune and immunodeficient diseases,365
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Third, the delayed onset of cGVHD is in many cases
complicated by comorbidities of allo-HSCT, such as
immune deficiency due to chronic immunosuppressive
therapy, infections, end-organ damage, and disease
relapse, which serve to alter the natural history of
cGVHD.
Importantly, defining the pathophysiology of
cGVHD has been complicated by the absence of ani-
mal models that completely recapitulate the disease
or its clinical setting, in contrast to aGVHD, where
murine models of major and minor histocompatability
(MHC) mismatched HSCT have provided a relatively
comprehensive picture of its pathophysiology as a clin-
ical disease [10]. Several factors contribute to the diffi-
culty of studying an animal model of cGVHD. To
date, no animal model described encompasses all of
the features observed in clinical cGVHD. Further-
more, the clinical relevance of animal models of
cGVHD based on preparative regimens, composition
of the donor graft, genetic backgrounds of donor and
host animals, posttransplant immune suppression,
and posttransplant events has been frequently called
into question. Despite these limitations, the study of
available models of cGVHD has provided insights
with respect to the pathogenesis of clinical cGVHD
that correlates with clinical observations. Further-
more, observations derived from studies in these
murine models have identified potential therapeutic
strategies in the management of clinical cGVHD.
The purpose of this review is to describe murine
models that have been used in the study of cGVHD,
the immunologic mechanisms that underlie each of
the graft-versus-host reactions (GVHR) that lead
to the cGVHD phenotypes, and their relevancy to
clinical cGVHD. These models are divided into
3 broad classifications (Table 2), based on phenotype
and immunologic mechanism, which encompass the
majority of murine cGVHDmodels that have been de-
scribed to date. For each, descriptions on how the
Table 1. Experimental Readouts in Murine Models of Acute and Chronic
GVHD
Acute GVHD Chronic GVHD
 Death  Longer term survival
 Severe acute morbidity
(weight loss, decreased
activity)
 Chronic morbidity
 Tissue pathology consistent
with necrosis in target
organs (gastrointestinal
tract, liver, skin)
 Chronic inflammatory
changes and fibrosis
(sclerodermatous skin
changes)
 Th1 cytokines (IFN-g, TNF-
a, IL-1b)
 Th2 cytokines
 Immune deficiency  Autoantibody production
 Antihost CTL reactivity  Lack of antihost CTL
reactivitymodel is established, their salient phenotypes and
pathophysiologic mechanisms, and their relevancy to
clinical cGVHD are discussed.
CD4 Stimulated B Cells and Autoantibody
Production in Systemic Lupus Erythematosus
(SLE)-cGVHD
Biology. One model that has been extensively uti-
lized in the study of cGVHD in mice involves adoptive
transfer of immune cells from MHC antigen disparate
donors. Although the use of MHC-mismatched cell
transfers in most cases result in a phenotype resem-
bling lethal aGVHD, in a number of models the trans-
fer of MHC-mismatched cells resulted in a phenotype
that resembles clinical SLE, hereafter termed SLE-
cGVHD. Most involve parent-into-F1 combinations,
resulting in mismatches in both class I and class II
MHC, whereby unfractionated peripheral immune
cells are adoptively transferred into nonirradiated
host mice. Another model resulting in a similar pheno-
type as the parent-into-F1 model utilizes coisogenic
mice that differ only in the class II MHC molecule as
a result of a mutant form of the class II I-A locus in
MHC [11-13]. The phenotype that arises from these
models is predominated by the generation of autoanti-
bodies directed against dsDNA, ssDNA, and chroma-
tin, and immune-complex glomerulonephritis [14,15].
Progressive idiopathic pneumonia syndrome (IPS) has
also been reported in a parent-into-F1 model of
GVHD [16,17].
The immunologic mechanisms that result in the
SLE-like phenotype in this model have been charac-
terized and shown to be distinct from the mechanisms
resulting in aGVHD in several ways (Figure 1). First,
the common characteristic of the mouse strain combi-
nations used in the SLE cGVHD models involve dis-
parities in class II MHC, indicating that stimulation
of CD4 T cells are important in SLE-cGVHD [18].
This was exemplified by experiments involving strain
combinations involving mutants in class I and class II
MHC. Lymph node cells and splenocytes from B6
mice were administered into nonirradiated (B6 
bm1)F1 hosts containing a mutated allele in class I
MHC or (B6  bm12)F1 hosts containing a mutated
allele in class II MHC. Whereas the B6 into (B6 
bm1)F1 transplant resulted in mild cGHVD, the B6
into (B6 bm12)F1 transplant resulted in a significant
cGVHD characterized by autoantibody production,
increased splenic weights, and higher numbers of anti-
body producing cells. In contrast, disparities in both
MHC class I and class II, that is, B6 into (bm1 
bm12)F1, resulted in an aGVHD phenotype [19]. De-
pletion of the donor inoculum of CD8 T cells but not
CD4 T cells resulted in autoantibody formation and
immune-complex glomerulonephritis, whereas both
CD4 and CD8 T cells were required for aGVHD
[20,21].
Table 2. Establishm
cGVHD Model ) Clinical Phenotypea References
SLE-cGVHD Auto Ab/ICG 18,22-38
IPS 16,17
aGVHD -. 23
cGVHD 11-13
Auto Ab/nephritis 53
Auto Ab/Scl
Scl-cGVHD Scl/fibrosisc 47,48,54,58-63,66,69, 75,76,78,80,82,84
Scl/fibrosis 49
Parotid Dysfxn. 52
Scl 64
Scl 82
Auto Ab/Scl 53
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Donor -. Recipient Strains Cells (Cell Dose) Radiation Dose (cGy
B6 -. (B6  DBA2)F1 Spl (8  107-1  108) only None
B6 -. (B6  DBA2)F1 TCD BM (1  107) 1 Spl
(5  106)
900
B6 -. (B6  BALB/c)F1 Spl (6  107) only None
bm12b -. B6 Spl (1  108) only None
DBA2 -. BALB/c Spl (5  107) only 650
B10.D2 -. BALB/c ±TCD BM (1  106 2 1 
107) 1 Spl (6  106 2 1  108)
700-1000
B10.D2 -. BALB/c 600
B10.D2 -. BALB/c Spl (2.5  107 2 1  108) only 850
[C3H.SW-.B6]CD4 -.
B6
Spl (2.5  107) only 1000
B6 -. CB6F1 TCD C3H.SW BM (5 
106) 1 CD4 (3  105)d
1100
DBA2 -. BALB/c TCD BM (5  106) 1 Spl
(3  106)
650
Spl (5  107) only
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sclerodermatous skin changes.
mbinations, preparative regimens, observed phenotypes, and cited references for SLE-cGVHD and Scl-cG
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rm of I-Ab b-chain of B6 TCR.
del includes fibrotic changes in lung, liver, salivary glands, and/or eye.
nduced by adoptively transferring CD41 cells from B6 mice that were recipients of TCD BM plus naı¨ve C
M from C3H.SW mice.
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Figure 1.Murine SLE-cGVHD. Illustrated are the events presumed to occur in the DBA2 into (B6DBA2)F1 model of SLE-cGVHD. DBA2
CD4 T cells are stimulated by host (B6 DBA2)F1 APC through interactions between peptide presented in the context of host class II MHC.
Activation of CD4T cells, in turn, stimulates host B cells to produce autoantibodies. In addition, B cells could stimulate additional donor CD4T
cells through antigen reprocessing and presentation in the context of its class IIMHC. In this way, the generation of autoantibodies against a pro-
gressively wider range of epitopes is perpetuated.Although CD4 T cells have been shown to be crit-
ical in the induction of SLE-cGVHD, CD8T cells ap-
pear to play an immunomodulatory role in that the
balance between CD4 and CD8 determines the ulti-
mate GVHD phenotype in this model. In support of
this, the most commonly studied strain combination
resulting in SLE-cGVHD involves the administration
of DBA2 (H-2d haplotype) splenocytes into (B6 
DBA2)F1 hosts (H-2bd haplotype) despite the fact
that there is complete mismatch at both MHC class I
and class II alleles. Paradoxically, adoptive transfer ex-
periments in the reciprocal direction, that is, B6 sple-
nocytes into (B6  DBA2)F1 hosts, results in an
aGVHD phenotype [18]. One factor that may account
for this is the lower frequency of precursor cytotoxic
T-lymphocytes (CTL) in the DBA2 compared to the
B6 inoculum [22]. The association of low precursor
CTL numbers with cGVHD and high precursor
CTL numbers with aGVHD has been demonstrated
in other parent into F1 models, although the courseand severity of the GVHD phenotype is variable
[23]. In addition to the notion that a paucity of host al-
loreactive CD8 T cells helps determine the GVH phe-
notype, DBA2-derived CD8T cells generate relatively
weak in vitro allogeneic responses, and more recent
studies suggest that induction of CD8 anergy results
in the shift from an aGVHD phenotype to an SLE-
cGVHD phenotype [24,25]. Finally, shifting the cyto-
kine balance in SLE-cGVHD from Th2 predominant
to Th1 predominant using systemic administration of
IL-12 at the time of adoptive transfer resulted in the
suppression of autoantibody production, normaliza-
tion of host splenic B and T cells, restoration of donor
antihost alloreactivity [26], and decreased severity of
immune-complex glomerulonephritis [27].
CD4 T cell activation and their interactions with
antibody producing B cells has been a major focus of
investigation in describing the pathophysiology of
SLE-cGVHD. Distinct from aGVHD, which is pre-
dominated by the activation and proliferation of type
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CD4 T cell activation in SLE-cGVHD results in the
production of type 2 helper T cells (Th2) producing
the cytokines IL-4 and IL-10 [28,29] that contribute
to polyclonal B cell activation (Table 1). The impor-
tance of B cell activity in SLE-cGVHD is supported
by a number of studies where B cell activation is dis-
rupted, including blockade of CD40 ligand [30],
blockade of T cell costimulation by CTLA4Ig [31],
stimulation of the tumor necrosis factor receptor
superfamily member 4-1BB [32], and the aforemen-
tioned skewing toward a Th1 predominant phenotype
with administration of IL-12. In these studies, inhibi-
tion of T cell-dependent antibody production resulted
in reversal of the SLE-cGVHD phenotype. Similarly,
promoting host B cell persistence by transferring per-
forin deficient T cells in the aGVHDmodel of B6 into
(B6  DBA2)F1 hosts resulted in a shift to a GVHD
phenotype resembling SLE-cGVHD [33].
Progression of SLE-cGVHD can occur by a num-
ber of mechanisms. First, B cells, being efficient anti-
gen presenting cells (APC), present multiple epitopes
of an individual antigen in the context of its class II
MHC, and can activate multiple clones of helper T
cells. These epitopes include reprocessed antigens or
peptides derived from immunoglobulins, both of
which are crossreactive with the original epitope. Acti-
vation of these T cells, in turn, can further promote B
cell activation and autoantibody production against
a progressively broader range of host-derived epitopes.
In this way, the generation of humoral responses
against host antigens is continuously perpetuated
[34-37]. Another proposed mechanism of SLE pro-
gression involves the inability to completely clear apo-
ptotic cells following GVHR from secondary immune
organs, thus providing an additional source of autoan-
tigens and further driving autoantibody production
[38].
Correlations to clinical cGVHD. The relevance
of the parent-into-F1 SLE-cGVHD model to clinical
cGVHD has been called into question for a number of
reasons. First, the absence of bone marrow-derived
stem cells in the donor inoculum and the absence of
any host immunodepletion prior to cell transfer is
inconsistent with the setting of clinical allo-HSCT.
Second, whereas some features of cGVHD following
allo-HSCT mimic SLE, the similarities are not
absolute. For example, the profile of autoantibody
expression in patients with cGVHD are highly hetero-
geneous, and includes autoantibodies associated with
other collagen vascular diseases [39,40]. Moreover,
the reported incidence of renal complications attribut-
able to cGVHD following allo-HSCT is relatively low
[1,41]. Third, the phenotype in the SLE-cGVHD
model arises from interactions between donor-derived
CD4 T cells and host-derived B cells, whereas donor-
derived B cells do not appear to be involved in thepathogenesis [13]. Similar interactions between T cells
and B cells have not been defined in the clinical setting
of mixed chimerism, and have not been consistently
observed in other models of murine cGVHD (see
below).
Despite these limitations, the SLE-cGVHD
model has contributed to the understanding of clinical
cGVHD in a number of ways. First, the model high-
lights the importance of B cells in contributing to the
SLE-cGVHD phenotype. In addition to the demon-
stration of autoantibodies in clinical cGVHD
[39,40], patients with extensive cGVHD were more
likely to have faster B cell recovery and detectable au-
toantibodies following allo-HSCT [42]. Treatment of
patients with refractory cGVHD with anti-CD20 chi-
meric monoclonal antibody (mAb; rituximab) resulted
in objective improvements in cGVHD [41]. Finally,
the SLE-cGVHD model could provide insights into
interactions between host and donor immune cells
that occur during immune recovery from allo-HSCT
following reduced intensity conditioning (RIC) where
transient or chronic states of mixed chimerism are
common [43-45]. For example, in a murine model of
MHC mismatched allo-HSCT utilizing RIC, there
was an association between the establishment of mixed
chimerism, high levels of autoantibody production,
and persistence of host B cells [46]. To date, however,
clinical correlates of these observations have not been
firmly established.
Pro-fibrotic pathways in sclerodermatous (Scl)-
cGVHD: Biology. Another model that has been
extensively used in the study of cGVHD in mice in-
volves the adoptive transfer of donor immune cells,
usually unfractionated splenocytes, into sublethally
irradiated host mice that are MHC matched but mis-
matched at loci encoding minor histocompatibility
antigens (miHA). The most common strain combina-
tion utilizes unfractionated splenocyte or purified T
cell populations from B10.D2 (H-2d) into BALB/c
(H-2d) hosts. Significant experimental model differ-
ences between the B10.D2 into BALB/c transplants
and the parent into F1 SLE-cGVHD model exist
(Table 2). First, transplant conditions differ in that
the B10.D2 into BALB/c model involves irradiation
of the host and the coadministration of donor bone
marrow in addition to splenocyte populations, result-
ing in full donor lymphoid chimerism. Thus, the ef-
fector arms of GVHD in the Scl-cGVHD model are
predominantly of donor origin in contrast to the
mixed chimerism that is established in the SLE-
cGVHD models. Moreover, with pretransplant radi-
ation, tissue damage and local inflammation in target
organs of cGVHD may play a role in the onset and
severity of the cGVHD phenotype. Second, the re-
sulting observed phenotypes are substantially differ-
ent from SLE-cGVHD. In contrast to autoantibody
production observed in the SLE-cGVHD model,
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type that encompasses many features of autoimmune
scleroderma. (For this reason, miHA mismatched
transplants resulting in a sclerodermatous phenotype
hereafter will be referred to as the Scl-cGVHD
model.) Fibrotic changes of the skin and other organs
including the gastrointestinal tract and the liver are
the phenotypic hallmarks in Slc-cGVHD, which
are detectable approximately 21 days following trans-
plant, and are characterized by loss of dermal fat, hair
follicle destruction, mononuclear cell infiltration, and
increased collagen deposition [47]. Additional mani-
festations include weight loss proportional to the do-
nor cell innoculum [47] and fibrosis of the lung [48],
liver and bile duct [49-51], and parotid salivary gland
[52]. Autoantibody production does not appear to
play a prominent role in the Scl-cGVHD model, al-
though immunoglobulin deposition at the dermoepi-
dermal junction and in the kidney has been observed
[47,53]. Significant mortality is observed as early as
6 weeks following transplant depending on the pre-
transplant radiation dose [54].
The known pathophysiologic mechanisms in-
volved in the Scl-cGVHDmodel are illustrated in Fig-
ure 2. Not surprisingly, given the distinct phenotypes
between the Slc-cGVHD and SLE-cGVHD models
and the differences in scientific approach, their patho-
physiologic mechanisms differ as well. Initially follow-
ing transplantation, occurring as early as 7 days
posttransplant and about 14 days prior to the onset
of skin lesions, inflammatory signals are released
from damaged tissue, including the chemokines
MCP-1, MIP-1a, and RANTES. As a result, infiltra-
tion of donor-derived mononuclear infiltration cells,
consisting of monocytes and activated macrophages
as well as T cells, occurs. Activated macrophages iso-
lated from sclerodermatous skin lesions are notable
for increased expression of scavenger receptors such
as ScR-A and MARCO, which in addition to their
functions in phagocytosis, can also participate in anti-
gen presentation [55,56]. The elevation of chemokine
expression in situ is accompanied by changes in the
expression of adhesion molecules in target organs
and their ligands on inflammatory cells [57]. For exam-
ple, compared with syngeneic transplant controls, ex-
pression of the cellular adhesion molecules VCAM-1
and ICAM-1 is increased in cGVHD target organs,
including the skin, liver, and gastrointestinal tract.
Concomitantly, expression of the ligands for these
VCAM-1 and ICAM-1, a4 integrin (as part of VLA-
4) and LFA-1 respectively, which are expressed by ac-
tivated lymphocytes, are also increased [58,59]. The
importance of the role of adhesion molecules in initi-
ating cGVHD was further demonstrated by the sys-
temic administration of mAb directed against
VCAM-1 prior to and following transplant. Mice
treated with the antibody had significantly reducedmortality and morbidity due to Scl-cGVHD com-
pared to untreated mice [60].
Investigation into the role of APC and their inter-
actions with T cells in Scl-cGVHD suggests a complex
interplay between donor-derived and recipient-de-
rived cell populations. With respect to T cells, do-
nor-derived naı¨ve CD4 T cells alone are sufficient
and necessary to generate Scl-cGVHD, consistent
with the SLE-cGVHD murine model and clinical ob-
servations that CD4 T cells play an important role in
cGVHD; CD8 T cells, as well as the effector/memory
fraction of CD4 T cells are insufficient to induce
cGVHD [61-63]. The role of CD4 T cells in cGVHD
is further supported in a murine model of cGVHD
progressing from aGVHD. Alloreactive CD4 T cells
generated in the setting of aGVHD, when transferred
into lethally irradiated secondary hosts, resulted in
a cGVHD phenotype [64]. With respect to APC, in
contrast to miHA mismatched models of murine
aGVHD, which are primarily dependent on host
APC for its initiation [65], both donor and host APC
are capable of eliciting cGVHD in the Scl-cGVHD
model. Moreover, using donor-host strain combina-
tions deficient in costimulatory molecules on APC,
the requirements for APC function in Scl-cGVHD
differ with respect to target organ. Whereas both do-
nor and recipient APC were sufficient to induce skin
cGVHD, donor APCwere found to be the primary in-
ducers of gut cGVHD. Costimulatory requirements of
T cells were also different between organs in that both
CD80/86 and CD40 costimulation of allospecific T
cells was required for initiation of gut cGVHD,
whereas CD80/86 alone was sufficient to induce skin
cGVHD [66]. From these studies, it is apparent that
differential patterns of inflammation at the various tar-
get tissues and subsequent T cell activation in draining
lymph nodes play an important role in defining the
pattern of host and donor derived APC and T cell re-
cruitment, and that this process appears to be tightly
regulated [67,68].
Genetic factors that define the presentation and
recognition of miHA appear to be critical determi-
nants in Scl-cGVHD manifestations. Transplants in-
volving donor-recipient strain combinations that
differ with respect to the pattern of immunodominant
antigen presentation dictated by MHC haplotype can
produce both aGVHD and cGHVD phenotypes. For
example, transplant of different B10 donor strains
into MHC-matched BALB recipient strains where
the only difference among the transplant pairs was in
MHC haplotype expression yielded distinct GVHD
phenotypes. Specifically, B10 (H-2b) into BALB.B
(H-2b), B10.BR (H-2k) into BALB.K (H-2k), and
B10.D2 (H-2d) into BALB/c (H-2d) transplants dif-
fered in clinical outcome in that the first 2 transplant
pairings resulted in systemic GVHD characterized
by diarrhea and hunched posture and little in the way
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Figure 2.Murine Scl-cGVHD. Illustrated are the events presumed to occur in the B10.D2 into BALB/c miHA mismatched transplant model.
Tissue damage results in the upregulation in inflammatory mediators and chemoattractants in target tissue and in adhesion molecules in mono-
cytes and donor-derivedT cells. Upon activation by donor and/or host APC (not shown in the figure), CD4T cells are recruited into target tissue
and signal activated macrophages to produce TGF-b by way of IL-13 signaling. TGF-b, in turn, binds to its receptor in fibroblasts resulting in
increased collagen synthesis, resulting in fibrosis. In addition to stimulation of collagen by fibroblasts throughTGF-b signaling, CD4T cells can
directly stimulate collagen synthesis by fibroblasts through IL-13 signaling. Clinical data demonstrating the role of stimulatory autoantibodies
against the PDGF receptor are also shown, but their role in murine cGVHD has not yet been demonstrated.of sclerodermatous skin changes that is characteristic
of the B10.D2 into BALB/C transplant pairing. Trans-
plants involving donor B10 hybrids and recipient
BALB hybrids, for example, (B10  B10.D2) F1 (H-
2bd) transplanted into (BALB.B  BALB/c)F1 (H-
2bd) recipients, resulted in a codominant expression
of the haplotype-specific GVHD phenotypes in that
recipient mice had both systemic and Scl-cGVHD
manifestations [69]. Analogously, patterns of T cell re-
ceptor (TCR) expression can also potentially play
a role in effecting the phenotype of GVHD. To illus-
trate this, the transfer of splenocytes derived from
DBA2 mice into sublethally irradiated BALB/c recipi-
ents results in a cGVHD phenotype that includes both
autoantibody production observed in the DBA2 into
(B6  DBA2)F1 model of SLE-cGVHD, but also
the fibrotic changes characteristic of the B10.D2 into
BALB/c model of Scl-cGVHD [53]. TCR repertoires
between DBA2 mice and B10.D2 mice differ withrespect to the expression of endogenous mouse mam-
mary tumor virus superantigens, resulting in deletion
of the TCR Vb gene segments, which in turn, confer
different patterns of immune responses depending on
the target antigen [70,71]. The diversity in TCR-
MHC:peptide combinations in these models likely
play a major role in the diversity of clinical cGVHD.
Moreover, expression of genes other than those in-
volved in antigen presentation and recognition may
play a role in affecting the phenotype of cGVHD
[72,73].
Fibrosis constitutes the ultimate outcome of the al-
logeneic immune response in Scl-cGVHD. Trans-
forming growth factor beta (TGF-b) plays a critical
role in the generation of fibrotic changes in the skin,
and shares commonality with other models of fibrosis
attributed to TGF-b signaling. TGF-b is secreted by
activated macrophages in an inactive form noncova-
lently bound to latency-associated protein (LAP).
the importance of this cytokine in promoting fibrotic
372 Y.-W. Chu and R. E. GressFollowing cleavage from LAP, TGF-b binds to its re-
ceptor on fibroblasts, and, via signaling mediated by
SMAD proteins, modulates collagen synthesis that
leads to fibrosis [74]. In murine Scl-cGVHD, disrup-
tion of the TGF-b signaling pathway using anti-
TGF-b antibodies or by systemic administration of
LAP significantly reduces the severity of skin disease
[48,75,76]. Additionally, TGF-b2mediated fibrosis
is controlled by Th2 CD4 T cells and is counterregu-
lated by Th1 CD4 T cells. The production of
TGF-b by activated macrophages may explain the
exacerbation of Scl-cGVHD in mice receiving spleno-
cytes from mice receiving granulocyte colony-stimu-
lating factor (G-CSF) as a model of allogeneic
peripheral blood stem cell transplant (allo-PBSCT),
where the severity of skin fibrosis is influenced by the
myelomonocytic fraction of the donor graft and is cor-
related with the degree of cutaneous CD11b1 cell in-
filtration [77,78]. Whereas the role of TGF-b in
mediating the skin changes Scl-cGVHD has been
well characterized, other cytokines secreted by Th2
CD4 T cells may have important roles in modulating
fibrosis. For example, IL-13 has been shown to be
a major mediator of fibrosis, either by directly stimu-
lating fibroblasts to produce collagen, or by indirectly
stimulating macrophages through the IL-13 receptor
to produce TGF-b [74]. Consistent with this, based
on sequential gene expression analysis in the skin of
Scl-cGVHD mice p57], IL-13 expression is elevated
in the early phases of cGHVD, although the precise
nature of IL-13’s functional role in fibrosis in this
model remains to be defined.
In addition to the interactions between T cells and
monocytes/macrophages that regulate fibrosis, there is
evidence generated from the Scl-cGVHD model that
mast cells and eosinophils may play a role in the induc-
tion of collagen synthesis leading to fibrosis. In vitro
studies suggest that both cell types can effect fibroblast
proliferation and collagen production [79]. In the skin
of Scl-cGVHDmice, mast cell infiltration and degran-
ulation that temporally correlated with the onset of
skin fibrosis was observed [47,80]. Eosinophilic infil-
tration of the liver was also reported in this model
[81]. Furthermore, treatment with the mast cell stabi-
lizer nedocromil sodium prior to and following
B10.D2 into BALB/c transplant resulted in ameliora-
tion of skin cGVHD [82]. Although the mechanisms
involving interactions among mast cells, eosinophils,
T cells, and fibroblasts in Scl-cGVHD remain unde-
fined, the murine Scl-cGVHD model provides an ex-
perimental platform to investigate these interactions
and identify additional targets for the treatment of
fibrosis.
In addition to the pro-fibrotic pathways as a major
manifestation in murine Scl-cGVHD, defects in im-
mune responses have also been observed. For example,
in a parent into F1 model of cGVHD, immune re-sponses to viruses were impaired because of impaired
tissue-specific homing of antigen-specific T cells,
which may partly explain the increased incidence in
opportunistic infections in patients with cGVHD
[83]. CD41 CD251 regulatory T cells may also play
an important role in the progression of disease pheno-
type. Reconstitution of BALB/c RAG knockout recip-
ients with donor B10.D2 CD41 CD251-depleted T
cells resulted in a more severe cGVHD phenotype
than unfractionated CD41 cells. Moreover, supple-
mentation of the donor graft with either donor or
host derived CD41 CD25- cells ameliorated the
cGVHD phenotype [84]. However, the mechanisms
by which regulatory T cells modulate Scl-cGVHD
remain undefined.
Correlations to clinical cGVHD. The Scl-
cGVHD model shares many phenotypic features
with the sclerodermatous form of clinical cGVHD,
which, in combination with poor performance status,
thrombocytopenia, hepatic dysfunction, and progres-
sive cGVHD onset from prior aGVHD, is an unfavor-
able prognostic factor for survival [85,86]. The
incidence of sclerodermatous cGVHD among all
long-term survivors of allo-HSCT is estimated to be
3%-10%, although both its incidence and severity
could be expected to rise with the increasing numbers
of unrelated donor transplants being performed and
the increased use of mobilized peripheral blood as
a stem cell source [87-90]. Sclerodermatous cGVHD
has also been reported following donor leukocyte infu-
sions (DLI) for relapsed disease [91], consistent with
the murine models Scl-cGVHD in which mature post-
thymic T cells are required for its pathogenesis.
Fibrosis is a feature frequently observed in multi-
ple organs in clinical cGVHD other than skin
[92,93]. There is also evidence that the mediators of fi-
brosis described in the murine Scl-cGVHD are similar
to that observed in clinical cGVHD. In vitro stimula-
tion of humanmononuclear cells with allogeneic fibro-
blasts and IL-4, which, like IL-13, is a pro-fibrotic
cytokine, results in increased collagen synthesis. Addi-
tion of IL-12, a potent inducer of Th1 activation,
suppressed this production [94]. Serum levels of
TGF-b are increased in patients with cGVHD follow-
ing allo-HSCT [95]. Interestingly, in allo-PBSCT, in
contrast to allo-BMT, which is associated with an in-
creased incidence and severity of cGVHD attributed
to the increased numbers of T cells in the donor allo-
graft [89,96], the incidence of GVHD was correlated
with the number of myelomonocytic-committed
CD341 progenitors [97], potentially providing an in-
creased source of TGF-b, although there was no dis-
tinction made between aGVHD and cGVHD.
Elevations in IL-13 were observed in the bronchoal-
veolar lavage fluid of recipients of lung transplants
with bronchiolitis obliterans [98], further suggesting
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serve to provide a rationale for cytokine-directed ther-
apy in sclerodermatous cGVHD [99]. Finally, stimula-
tory autoantibodies to the platelet-derived growth
factor (PDGF) receptor have been found in patients
with extensive sclerodermatous cGVHD as well as pa-
tients with systemic sclerosis that was associated with
increased collagen gene expression [100,101].
Whether these stimulatory autoantibodies exist in mu-
rine Scl-cGVHD models remains to be determined.
One limitation to the murine Scl-cGVHD model
is that it generally parallels a severe form of clinical
cGVHD that is found in only a subset of allo-HSCT
recipients with cGVHD. The clinical spectrum of
clinical cGVHD is extremely broad with respect to se-
verity and extent [1,3,9], and cutaneous manifestations
of cGVHD are likewise highly variable [102]. More-
over, the clinical manifestations of cGVHD may be
influenced by iatrogenic factors including preparative
regimen and stem cell source [44,89,103,104]. It would
be of interest if the spectrum of cGVHD phenotypes
can be recapitulated in murine cGVHD models that
incorporate these clinically relevant variables. Finally,
as was previously detailed, genetic heterogeneity in
stem cell donors and recipients play a critical role in
determining cGHVD phenotype. Although this factor
cannot be fully recapitulated in murine models, the use
of inbred mouse trains in combinatorial donor-recipi-
ent transplant pairings provides insight into the influ-
ence of miHA mismatch on the clinical outcome of
allo-HSCT with respect to GVHD, and may serve as
a model to identify the nature of individual miHA de-
terminants that are important in the development of
cGVHD.
cGVHD caused by defects in thymic function:
biology. The thymus, in addition to being the pri-
mary site of T cell development, is also a major site
of tolerance induction to self-antigens through the
negative selection of autoreactive T cell clones. Nega-
tive selection is regulated through tissue restricted an-
tigen expression on thymic epithelial cells and thymic
dendritic cells [105]. Because of its role in central tol-
erance, the thymus is viewed as an organ critical for the
initiation and propagation of GVHD by the produc-
tion of autoreactive T cells resulting from impaired
negative selection following treatment-related or im-
mune mediated damage. Evidence for this comes in
part from the observation that mice thymectomized
during the neonatal period spontaneously develop
multiorgan autoimmune disease [106].
Although murine models of aGVHD have directly
shown that the thymus is indeed structurally and func-
tionally adversely affected by the presence of donor-
derived alloreactive immune cells [107-110], the
effects of cGVHD on thymic function are less clear.
Whereas some clinical studies have associated
cGVHD with impairment of thymic function [111-113], others have attributed the low numbers of recent
thymic emigrants seen in clinical cGVHD to their im-
paired survival in the peripheral immune system rather
than decreased thymic function [114]. Yet another
possibility is that bone marrow derived T cell progen-
itors are unable to effectively home to the thymus in
the setting of cGVHD [83]. Additionally, the role of
thymic dysfunction itself on the pathogenesis of
cGVHD in humans has not been clearly established.
Interestingly, the murine models described in this
review thus far have not clearly defined a thymic role
in the induction of cGVHD. In the DBA2 into (B6
 DBA2)F1 model of SLE-cGVHD, there were no
apparent effects on thymic cytoarchitecture and T
cell development in contrast to the B6 into (B6 
DBA2)F1 model of aGVHD [108]. Similarly, in the
miHA mismatched murine Scl-cGVHD models, thy-
mic production of donor-derived T cells was not nec-
essary for induction of the phenotype. In the B10.D2
into BALB/c model, donor bone marrow cells alone
without postthymic T cells did not result in cGVHD
associated phenotypic changes [66], whereas adminis-
tration of DBA2 splenocytes and bone marrow cells
into thymectomized BALB/c hosts did not change
the incidence or severity of cGVHD when compared
to thymus-intact mice. However, in these mice, thymic
cellularity was adversely affected by cGVHD, al-
though more specific parameters of thymic function
such as the enumeration of recent thymic emigrants
by T cell receptor excision circle quantitation or eval-
uations of T cell receptor repertoire diversity were not
performed [53].
A murine model of cGVHD attributed to thymic
dysfunction has recently been described, whereby le-
thally irradiated C3H/HeN recipients received T
cell-depleted bone marrow from MHC-mismatched
B6 mice deficient in MHC class II antigens (B6 H-2
Ab12/2). As a consequence of impaired thymic nega-
tive selection resulting from the absence of MHC class
II on host-derived thymic dendritic cells (DC), many
features clinical cGVHD were observed. These fea-
tures included sclerodermatous skin changes, weight
loss, bile duct loss and fibrosis, inflammation and
mononuclear cell infiltration of the salivary glands,
and increased mortality (Figure 3). Transplantation
of B6 H-2 Ab12/2 bone marrow into thymectomized
recipients did not result in cGVHD, whereas trans-
plantation of wild-type B6 bone marrow resulted in
a less severe cGVHD phenotype. Furthermore, adop-
tive transfer of CD4 T cells generated in the cGVHD
mice and donor APC into secondary irradiated C3H/
HeN recipients resulted in the cGVHD phenotype.
Thymic regulatory T cell production was not affected
but was insufficient to inhibit cGVHD. Autoantibody
production was not reported in this model [115].
To date, the B6 H-2 Ab12/2 into C3H/HeN
transplant model is the only 1 described that directly
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Figure 3.ChronicGVHDcaused by thymus dysfunction. The thymus is critical for central tolerance. Damage to the thymus by radiation and/or
infiltration of donor alloreactive T cells results in thymic damage that leads to impaired negative selection and T cell development as modeled by
transplantation of thymic DC lacking class IIMHC. Impaired negative selection leads to the development of host-derived donor reactive T cells,
which, upon activation with donor-derived APC, leads to cGVHD.links aberrant thymic function with induction of
a cGVHD phenotype, and suggests a role for donor-
derived APC as an important variable in modulating
central tolerance and peripheral stimulation of do-
nor-derived T cells against host antigens following
allo-HSCT, although the exact mechanism is not
known. Although the model demonstrates that the
complete abrogation of negative selection of CD4 T
cells induces cGVHD, a number of caveats related to
the role of the thymus in cGVHD are worth consider-
ing. First, none of the murine models of cGVHD in-
volving genetically unmodified mice has provided
evidence of impaired negative selection that would
lead to cGVHD. It remains to be seen whether exper-
imental conditions exist that result in observable thy-
mic dysfunction contribute to or alter the cGVHD
phenotype in these models. Second, the clinical rele-
vance of the B6 H-2 Ab12/2 into C3H/HeN trans-
plant model is limited by the fact that thymic
function is perpetually impaired by the absence of
MHC class II antigen on APC beyond the period
when complete regeneration of thymic function occurs
[116]. It is not clear, for example, whether there exists
a temporal ‘‘window’’ of thymic damage followed by
recovery during which deficits in negative selection
are necessary and/or sufficient to induce cGVHD.
Moreover, it is not known if the thymus in the B6 H-
2 Ab12/2 into C3H/HeN transplant model is itselfa target of GVHD, because negative selection is not
only mediated by donor-derived DC, but also host
medullary thymic epithelium [105]. Finally, the clini-
cal relevance of this model is unclear given that thymic
function declines with age and is questionably present
in older individuals undergoing allo-HSCT who de-
velop cGVHD. Nevertheless, observations from this
model suggest that enhancements in thymic function
following allo-HSCT through the administration of
positive thymic regulators may play a role in amelio-
rating clinical cGVHD [64]. Clinical studies involving
administration of positive thymic regulators in the
posttransplant setting will be able tomore fully charac-
terize the role of thymic dysfunction in the induction
and/or progression of cGVHD.
CONCLUDING REMARKS
Clinical cGVHD is an extremely complex and di-
verse disease, which makes the establishment of mu-
rine models that recapitulate all features of the
disease difficult to establish. Murine models of
cGVHD have been useful in identifying many of the
pathophysiologic mechanisms involved in autoanti-
body production and fibrotic changes, 2 features com-
monly found in cGVHD. However, important clinical
variables attributed to the development of cGVHD in
humans are difficult to accurately reproduce in mice,
Murine Models of Chronic Graft-versus-Host Disease 375and to date, nomurine model encompasses all of them.
Additionally, methods in RIC and the use of mobilized
PBSC, which have been shown to influence the inci-
dence and spectrum of clinical cGVHD, have yet to
be recapitulated in murine models. Similarly, cGVHD
evolved from aGVHD, which has potentially impor-
tant implications in defining the role of thymic func-
tion in cGVHD, has also yet to be modeled in mice.
As the clinical spectrum of cGVHD continues to be
characterized in a systematic way with respect to clin-
ical features, pathologic examination, and biomarkers,
it is likely that novel murine transplant models will be
successfully developed to recapitulate these features,
and identify additional potential targets for therapeutic
intervention in the management of clinical cGVHD.
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